Annual Information Update

Oxford Biomedica PLC
17 April 2007


           Oxford BioMedica plc ('Oxford BioMedica' or the 'Company')


        Annual Information Update for the Twelve Months to 2 April 2007


This annual information update is filed pursuant to Prospectus Rule 5.2 made by
the Financial Services Authority and not for any other purpose and by filing
this annual information update neither the Company, nor any other person, takes
any responsibility for, or makes any representation, express or implied, as to
the accuracy or completeness of, the information contained or referred to below
herein. The information referred to below is not necessarily up to date as at
the date of this annual information update and the Company does not undertake
any obligation to update any such information in the future. Furthermore, such
information may have been prepared in accordance with the laws or regulations of
a particular jurisdiction and may not comply with or meet the relevant standards
of disclosure in any other jurisdiction. Neither this annual information update,
nor the information referred to below constitutes, by virtue of this
communication, an offer of any securities addressed to any person and should not
be relied on by any person.


1. Announcements made via a Regulatory Information Service

Date                           Announcement

30 March 2007                  Total voting rights update
29 March 2007                  Notice of AGM
28 March 2007                  Agreement to develop TroVax
20 March 2007                  Holding(s) in Company
16 March 2007                  Holding(s) in Company
16 March 2007                  Holding(s) in Company
15 March 2007                  Re acquisition of Oxxon Therapeutics Limited
12 March 2007                  Acquisition of Oxxon Therapeutics Limited
6 March 2007                   Preliminary results for 2006
28 February 2007               Total voting rights update
27 February 2007               Holding(s) in Company
27 February 2007               Notice of results
22 February 2007               Holding(s) in Company
20 February 2007               Holding(s) in Company
14 February 2007               Holding(s) in Company
9 February 2007                Holding(s) in Company
7 February 2007                Holding(s) in Company
1 February 2007                Result of EGM
31 January 2007                Total voting rights update
24 January 2007                Holding(s) in Company
24 January 2007                Avian Transgenic project milestone
16 January 2007                Publication results from avian transgenic programme
10 January 2007                Phase III trial in TroVax adopted in UK by NCRN
4 January 2007                 Total voting rights update
2 January 2007                 Total voting rights amendment
22 December 2006               Total voting rights statement
21 December 2007               LentiVector licence signed with GlaxoSmithKline
19 December 2006               Holding(s) in Company
19 December 2006               Lentivector licence with major drug company expanded
8 December 2006                Holding(s) in Company
8 December 2006                TroVax positive EU orphan drug recommendation
5 December 2006                Holding(s) in Company
21 November 2006               Blocklisting interim review
13 November 2006               ProSavin preclinical data presented
9 November 2006                TroVax phase II data presented
7 November 2006                TroVax commencement of phase III trial
6 October 2006                 TroVax phase II data presented
2 October 2006                 Expansion of ocular disease programme and shares
                               subscription
25 September 2006              Holding(s) in Company
20 September 2006              Holding(s) in Company
7 September 2006               Directors' interests in share options
5 September 2006               Interim results
5 September 2006               TroVax phase II trial update re SWOG breast cancer trial
21 August 2006                 TroVax phase II data presented
3 August 2006                  Holding(s) in Company
31 July 2006                   Update and clarification on TroVax
18 July 2006                   Holding(s) in Company
6 July 2006                    Holding(s) in Company
5 July 2006                    Director/PDMR shareholding
29 June 2005                   Holding(s) in Company
26 June 2006                   Holding(s) in Company
26 June 2006                   ProSavin patent notice of allowance
21 June 2006                   Oxford BioMedica to present at Piper Jaffray healthcare
                               conference
14 June 2006                   Oxford BioMedica and Sigma-Aldrich suit against Open
                               Biosystems
12 June 2006                   Holding(s) in Company
7 June 2006                    TroVax phase II results presented
23 May 2006                    TroVax phase II trial in prostate cancer starts
22 Mat 2006                    Holding(s) in Company
18 May 2006                    Blocklisting interim review
16 May 2006                    Director/PDMR shareholding
12 May 2006                    TroVax receives Special Protocol Assessment for phase III
                               trial in renal cancer
4 May 2006                     AGM statement
2 May 2006                     RetinoStat preclinical data presented
20 April 2006                  Holding(s) in Company
11 April 2006                  Annual report 2005 lodged with FSA
11 April 2006                  Annual information update



Details of all regulatory announcements for Oxford BioMedica can be found on the
London Stock Exchange website at www.londonstockexchange.com and on the Oxford
BioMedica website at http://www.oxfordbiomedica.co.uk


2. Documents filed with Companies House

Date               Document Type                        Description

28 February 2007  88(2) Return of Allotment of shares  Allotment 313,017 1p Ord.
28 February 2007  88(2) Return of Allotment of shares  Allotment 82,007 1p Ord.
10 January 2007   288a Appointment of director         Dr Michael McDonald
15 December 2006  88(2) Return of Allotment of shares  Allotment 111,864 1p Ord.
13 December 2006  88(2) Return of Allotment of shares  Allotment 266,124 1p Ord.
17 November 2006  88(2) Return of Allotment of shares  Allotment 173,140 1p Ord.
17 November 2006  88(2) Return of Allotment of shares  Allotment 485,185 1p Ord.
17 November 2006  88(2) Return of Allotment of shares  Allotment 357,583 1p Ord.
17 November 2006  88(2) Return of Allotment of shares  Allotment 348,435 1p Ord.
17 November 2006  88(2) Return of Allotment of shares  Allotment 25,490 1p Ord.
17 November 2006  88(2) Return of Allotment of shares  Allotment 1,023,870 1p Ord.
17 November 2006  88(2) Return of Allotment of shares  Allotment 64,864 1p Ord.
17 November 2006  88(2) Return of Allotment of shares  Allotment 49,895 1p Ord.
 20 October 2006  363s Annual Return


Copies of documents filed at Companies House can be obtained from Companies
House, Crown Way, Cardiff CF14 3UZ or through Companies House Direct at
www.direct.companieshouse.gov.uk


3. Documents published or sent to shareholders or filed with the UKLA Viewing
Facility

Date                Description
2 April 2007        Annual Report - year ended 31 December 2006 and Notice of 
                    Annual General Meeting
10 January 2007     Notice of Extraordinary General Meeting
5 September 2006    Interim Report for 6 months to 30 June 2006
6 April 2006        Annual Report - year ended 31 December 2005 and Notice of 
                    Annual General Meeting



Copies of all the above documents may be obtained from the Company Secretary at
the Company's Registered Office:


Oxford BioMedica plc
Medawar Centre
Robert Robinson Avenue
The Oxford Science Park
Oxford
OX4 4GA

17 April 2007



                      This information is provided by RNS
            The company news service from the London Stock Exchange